Fosbretabulin Disodium
Get Fosbretabulin Disodium essential facts below. View Videos or join the Fosbretabulin Disodium discussion. Add Fosbretabulin Disodium to your topic list for future reference or share this resource on social media.
Fosbretabulin Disodium
Combretastatin A-4 phosphate
Combretastatin A-4 phosphate.svg
Clinical data
Other namesCA4P; CA4PD; fosbretabulin; fosbretabulin disodium
PubChem CID
Chemical and physical data
Molar mass396.32 g/mol (exact mass : 396.097404) g·mol-1
3D model (JSmol)
For more information about this drug and its actions, see combretastatin.

Combretastatin A-4 phosphate (fosbretabulin, and its salt fosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.

Combretastatin A-4 phosphate (CA4P) is a prodrug. In vivo, it is dephosphorylated to its active metabolite, combretastatin A-4.[1]

CA4P is also known as Fosbretabulin Tromethamine.[2]

In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer.[3] There is currently no fully FDA approved treatment for this form of cancer.

By 2017 it had completed multiple clinical trials (e.g. for solid tumours,[4] non-small cell lung cancer[5]) with more in progress.[6]

See also


  This article uses material from the Wikipedia page available here. It is released under the Creative Commons Attribution-Share-Alike License 3.0.



Music Scenes